Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection

NCT02340962 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: TG-2349
DRUG: Ribavirin
DRUG: Interferon Alfa-2a

Sponsor

TaiGen Biotechnology Co., Ltd.